Apart from clinical predictors such as PSA value, localization and number of PSMA-avid lesions there have been indications for molecular and genetic predictors of clinical outcome in metastatic prostate cancer [25, 26]. This evidence concerns the gene KLK3 and metastatic prostate carcinoma.